[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital Xi'an Jiaotong University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":652},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,47,69,100,125,150,178,205,232,259,282,310,335,360,383,403,433,460,486,513,540,562,587,607,626],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100568659","ursodeoxycholic-acid-attenuates-statin-induced-impaired-glucose-tolerance-100568659",false,"NCT06684106","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance: A Randomized Controlled Clinical Trial","URSTAR","Inclusion Criteria:\n\n* Age 18-75 years old.\n* LDL-C≥3.4mmol\u002Fl (130 mg\u002FdL).\n* Glycosylated hemoglobin ≤ 6.0% (42 mmol\u002Fmol).\n* Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Previous diagnosis of diabetes or prediabetes.\n* Past or current use of hypoglycemic drugs.\n* Oral administration of statin lipid-lowering drugs within three months before enrollment.\n* Combined oral drug quantity ≥3.\n* History of ASCVD (previous myocardial infarction, ACS, stroke or TIA within 1 year, symptomatic peripheral vascular disease).\n* Active liver disease (defined as elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\>2 × upper limit of normal (ULN) from any existing known liver infectious, neoplastic, or metabolic pathologic cause or unknown cause at the time of screening), Severe hepatic insufficiency and biliary obstruction.\n* Difficult to control hypertension: defined as systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite antihypertensive therapy prior to randomization.\n* Estimated glomerular filtration rate (eGFR) ≤ 30 mL\u002Fmin\u002F1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method\n* New York Heart Association (NYHA) Class IV heart failure or a known left ventricular ejection fraction \\\u003C 25%\n* A clinically significant and drug- or ablation-resistant arrhythmia within 3 months prior to randomization\n* An acute or severe systemic infection, or any of the following diseases: hematological disorders, autoimmune disorders, malignant tumors, psychiatric patients, or other serious or unstable conditions that could impact study health status\n* Scheduled for surgery within 6 months\n* Pregnant, breastfeeding, or trying to become pregnant during the study or within 6 months of study completion\n* Subjects with alcohol or other drug addiction\n* Secondary hypercholesterolemia, such as hypothyroidism or nephrotic syndrome\n* A history of allergic reaction to any study drug or its excipients or similar chemical classes of drugs\n* A family history of homozygous familial hypercholesterolemia\n* Participants currently enrolled in another clinical trial, or who cannot adhere to 6-month follow-up\n* Any condition that the investigator considers unsuitable for participation.",true,"ALL","18 Years","75 Years",{"count":23,"type":24},128,"ESTIMATED","INTERVENTIONAL",[27],"NA","The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:\n\n* Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins?\n* Will the use of UDCA decrease other adverse events in patients taking oral statins?\n\nParticipants will:\n\n* Take Atorvastatin combined with UDCA or a placebo daily for 6 months\n* Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.",[30,31,32,33],"Hyperlipidemia","Ursodeoxycholic Acid","Statin Therapy","Glucose Intolerance","RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2024-11-25",{"date":42,"type":24},"2027-06-01",{"name":44,"class":45},"First Affiliated Hospital Xi'an Jiaotong University","OTHER",2,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100637624","diagnostic-study-of-structural-heart-disease-based-on-cardiac-electromechanical-signals-100637624","NCT07603115","Diagnostic Study of Structural Heart Disease Based on Cardiac Electromechanical Signals","Inclusion Criteria:\n\n* \\- Aged ≥ 18 years.\n* For the case group: Presence of valvular lesions confirmed by transthoracic echocardiography.\n* For the control group: Normal cardiac valves and no evidence of other cardiovascular diseases confirmed by transthoracic echocardiography.\n* Ability to undergo and complete speckle tracking echocardiography.\n\nExclusion Criteria:\n\n* Patients who are unwilling to participate in this study.\n* Patients with a known allergy to the electrode patches or medical adhesive tapes used in this study.\n* Patients who are unable to cooperate with the completion of required examinations.\n* Patients with incomplete clinical or imaging data that cannot be supplemented.","85 Years",{"count":55,"type":24},1300,"OBSERVATIONAL","Study participants will be prospectively recruited from consecutive outpatient and inpatient populations presenting to the Cardiology and Cardiac Surgery Departments of the following participating institutions: The First Affiliated Hospital of Xi'an Jiaotong University, The Second Affiliated Hospital of Xi'an Jiaotong University, and \\[add additional participating institutions as applicable\\].",[59],"Valvular Heart Disease","NOT_YET_RECRUITING","2026-05-21",{"date":63,"type":38},"2026-05-22",{"date":65,"type":24},"2026-05",{"date":67,"type":24},"2027-12",{"name":44,"class":45},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":25,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100635362","efficacy-of-thrombus-aspiration-in-patients-with-acute-st-segment-elevation-myocardial-infarction-a-prospective-multicenter-randomized-controlled-single-blind-clinical-trial-100635362","NCT07551700","Efficacy of Thrombus Aspiration in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized, Controlled, Single-Blind Clinical Trial","Efficacy of Thrombus Aspiration in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized, Controlled, Single-Blind Clinical Trial (TRAP-MI)","TRAP-MI","Inclusion Criteria:\n\n* Aged ≥18 years old, diagnosed with acute ST-segment elevation myocardial infarction (STEMI) (chest pain plus ST-segment elevation ≥1mm or new-onset left bundle branch block \\[LBBB\\]) with symptom onset \\\u003C 12 hours.\n* Planned to undergo primary percutaneous coronary intervention (PPCI).\n* High thrombus burden in the target vessel (TIMI thrombus grade ≥3, or visible floating thrombus) confirmed by coronary angiography.\n* Reference diameter of the target vessel ≥2.75mm, with the lesion suitable for the passage of an aspiration catheter.\n* Provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Cardiogenic shock (Killip class IV) or requiring mechanical circulatory support.\n* A history of previous coronary artery bypass grafting (CABG).\n* Concurrent intervention required for non-culprit vessels.\n* Severe bleeding tendency (e.g., INR \\> 2.5, platelet count \\\u003C 50×10⁹\u002FL).\n* Severe renal insufficiency (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 ml\u002Fmin\u002F1.73m²).\n* Expected survival time \\\u003C 1 year (e.g., advanced malignant tumor).",{"count":78,"type":24},6760,[27],"The goal of this clinical trial is to learn if adding standardized manual thrombus aspiration to primary percutaneous coronary intervention (PPCI) works better to improve heart health outcomes and protect long-term heart function in adults with acute ST-segment elevation myocardial infarction (STEMI) and a high blood clot burden in the heart's arteries. The main questions it aims to answer are:\n\n* Does PPCI plus manual thrombus aspiration lower the risk of serious heart problems one year after treatment, compared to PPCI alone?\n* Can manual thrombus aspiration better protect long-term heart function in people with a high blood clot burden? Researchers will compare two groups of participants-one group getting PPCI plus manual thrombus aspiration and one group getting only PPCI-to see if the aspiration treatment leads to fewer serious heart problems, better long-term heart function, and similar safety (including no higher risk of stroke).\n\nParticipants will:\n\n* Have a heart artery scan (coronary angiography) to confirm a high blood clot burden\n* Be randomly assigned to one of the two treatment groups for their PPCI procedure\n* Complete follow-up checks at 30 days, 6 months, and 1 year after treatment, including heart function tests (like echocardiograms)\n* Have heart magnetic resonance (CMR) scans if selected, to measure heart tissue damage and heart function\n* Have their heart health status and any adverse events recorded throughout the study",[82],"ST-segment Elevation Myocardial Infarction (STEMI)",[84,85,86,87,88,89,90,91],"Acute ST-Segment Elevation Myocardial Infarction","STEMI","Thrombus Aspiration","Primary Percutaneous Coronary Intervention","PPCI","High Thrombus Burden","Randomized Controlled Trial","Multicenter Trial","2026-04-20",{"date":94,"type":38},"2026-04-27",{"date":96,"type":24},"2026-04-01",{"date":98,"type":24},"2028-12-31",{"name":44,"class":45},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":25,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100634648","study-of-thiotepa-combination-with-melphalan-tm-protocol-conditioning-for-autologous-hematopoietic-stem-cell-transplantation-in-multiple-myelomaa-prospective-randomized-controlled-clinical-trial-100634648","NCT07542418","Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* 1\\) Age 18-70 years old, gender is not limited; 2) Patients with confirmed multiple myeloma; 3) CR is not achieved before transplantation after treatment with or without extramedullary lesion invasion; 4) plan to undergo autologous hematopoietic stem cell transplantation; 5) recieve autologous hematopoietic stem cell transplantation within 12 months; 6) CD34 positive cell counts ≥2×106\u002Fkg; 7) The function of major organs is normal, and the laboratory test results meet the following criteria: a. Alanine aminotransferase (ALT) ≤3.0× upper limit of normal (ULN) aspartate aminotransferase (AST) ≤3.0×ULN; b. Serum total bilirubin ≤ 1.5×ULN; 8) Voluntarily participate in this clinical trial, understand the research procedures and be able to sign the informed consent forms\n\nExclusion Criteria:\n\n* 1\\) Do not have indications for autologous hematopoietic stem cell transplantation; 2) presence of uncontrolled active infection (HIV-positive, positive for HBV-DNA and HCV-RNA quantitative tests); 3) severe respiratory diseases; 4) Severe abnormal liver function; 5) a second transplant is required; 6) Clinically significant or uncontrolled heart disease (grade III or IV congestive heart failure, EF\\\u003C45%, BNP\\>5000ng\u002Fml, TnT\\>0.06ug\u002FL, oxygen saturation \\\u003C95%, any of which) 7) Patients with other solid tumors; 8) Those who are allergic to setepa and the drug involved in the study or have a more serious allergic constitution; 9) Those who participate in other clinical research at the same time; 10) Other conditions judged by the investigator to be unsuitable for inclusion in this study.","70 Years",{"count":108,"type":24},204,[27],"To explore the efficacy and safety of thiotepa combined with melphalan for ASCT conditioning in patients with multiple myeloma who did not acheive CR with or without extramedullary inflitration before transplantation.\n\nAfter screening and enrollment, the patients were randomly divided into two groups according to 1:1, and the experimental group received the following drug treatments: the total amount of thiotepa was 10mg\u002Fkg, D-4 to -3; melphalan 140mg\u002Fm2, D-2. The control group received melphalan 200mg\u002Fm2, D-2 (the dose of the drug was adjusted according to the glomerular filtration rate). The two groups of D0 infused hematopoietic stem cells.G-CSF and TPO or TPO-RA were allowed to use to promote hematopoietic stem cell engraftment.Platelet and red blood cell transfusions were allowed if necessary. Efficacy of the therapy was evaluated 1 month after the end of transplantation, and the follow-up evaluation was carried out every 3 months, and the relapse rate was evaluated until 1 year after transplantation.",[112],"Multiple Myeloma",[114,115,116,117],"autologous stem cell transplantation","thiotepa","melphalan","conditioning","2026-04-14",{"date":120,"type":38},"2026-04-21",{"date":92,"type":24},{"date":123,"type":24},"2028-10-20",{"name":44,"class":45},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":25,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100631672","phase-3-early-use-of-realgar-indigo-naturalis-formula-rif-combined-with-all-trans-retinoic-acid-atra-for-treating-acute-promyelocytic-leukemia-apl-100631672","NCT07503730","Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).","Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)","EARLY-RIF APL","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Diagnosed with acute myeloid leukemia confirmed by bone marrow morphology and immunophenotyping, with a high clinical suspicion of acute promyelocytic leukemia (APL).\n\nExclusion Criteria:\n\n1. Confirmed non-APL (M3 type) acute myeloid leukemia through cytogenetic and RT-PCR testing (PML-RARα fusion gene negative).\n2. Severe liver or kidney dysfunction unrelated to APL (e.g., serum creatinine \\> 2.5 times the upper limit of normal, total bilirubin ≥ 2 times the upper limit, ALT and AST \\> 3 times the upper limit), or heart failure (e.g., EF \\\u003C 40%).\n3. Presence of other malignancies.\n4. Pregnant or breastfeeding women.","80 Years",{"count":135,"type":24},224,[137],"PHASE3","Study Title:\n\nMulticenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)\n\nSponsor:\n\nXi'an Jiaotong University First Affiliated Hospital\n\nPrincipal Investigator:\n\nWang Huaiyu\n\nStudy Description:\n\nThis multicenter, randomized controlled trial evaluates whether early induction treatment with oral Realgar-Indigo Naturalis Formula (RIF) combined with all-trans retinoic acid (ATRA) reduces early death rates in patients with acute promyelocytic leukemia (APL). APL is a subtype of acute myeloid leukemia characterized by a high risk of early death, largely due to coagulopathy and bleeding events, especially in high-risk patients with elevated white blood cell counts.\n\nTraditional treatment with ATRA and arsenic trioxide (ATO) has improved outcomes but early mortality remains a major challenge. RIF, an oral arsenic compound Chinese patent medicine, has demonstrated efficacy comparable to ATO with advantages in safety and oral administration convenience. Previous smaller studies suggested RIF may accelerate recovery of coagulation parameters and reduce early death.\n\nPatients clinically suspected of APL will be randomized into two groups:\n\nExperimental group: oral ATRA + RIF before molecular diagnosis confirmation\n\nControl group: oral ATRA only before confirmation\n\nAfter molecular or genetic diagnosis confirmation:\n\nExperimental group receives 1 week of ATRA + RIF induction (days 0-7), then switches to 3 weeks ATRA + ATO (days 8-28)\n\nControl group receives 4 weeks ATRA + ATO (days 0-28)\n\nBoth groups then receive identical consolidation therapy with ATRA + ATO for 6 cycles (2 weeks treatment + 2 weeks off per cycle) following molecular complete remission.\n\nPrimary Objective:\n\nTo evaluate whether early induction with ATRA + RIF reduces early death rate (within 30 days of diagnosis) in APL patients.\n\nSecondary Objectives:\n\nTo explore if early ATRA + RIF (prior to molecular confirmation) is non-inferior to ATRA alone in reducing coagulopathy and early death in suspected APL patients. Secondary endpoints include 2-year event-free survival (EFS) and overall survival (OS).\n\nStudy Design:\n\nType: Multicenter, randomized, open-label controlled clinical trial\n\nPopulation: Adults aged 18-80 years with newly diagnosed acute myeloid leukemia highly suspected as APL\n\nRandomization: Central randomization assigns participants to experimental (ATRA + RIF) or control (ATRA only) groups\n\nBlinding: Open-label (no blinding)\n\nInclusion Criteria:\n\nAge 18-80\n\nNewly diagnosed AML with strong clinical suspicion of APL based on bone marrow morphology and immunophenotyping\n\nExclusion Criteria:\n\nNegative for PML-RARα fusion by cytogenetics or RT-PCR\n\nSevere organ dysfunction not related to APL (renal, hepatic, cardiac)\n\nQTc \\>480 ms before treatment\n\nOther malignancies\n\nPregnant or breastfeeding women\n\nTreatment Regimen:\n\nInduction: Experimental group receives oral ATRA 25 mg\u002Fm²\u002Fday + RIF 60 mg\u002Fkg\u002Fday for 7 days, then ATRA + intravenous ATO 0.15 mg\u002Fkg\u002Fday for 3 weeks; Control group receives ATRA + ATO for 4 weeks.\n\nConsolidation:During the consolidation phase, intermediate- and low-risk patients receive either intravenous ATO or oral RIF, while high-risk patients receive intravenous ATO together with intravenous mannitol infusion. Routine lumbar puncture and intrathecal chemotherapy are not performed.\n\nSupportive care includes hydroxyurea and venetoclax for elevated WBC, transfusions for coagulopathy, and dexamethasone for differentiation syndrome.\n\nEndpoints:\n\nPrimary endpoint: Early death rate (death within 30 days of diagnosis)\n\nSecondary endpoints: 2-year event-free survival (EFS), 2-year overall survival (OS)\n\nSample Size:\n\nApproximately 224 patients (112 per group), calculated to detect a reduction in early death rate from 12% (historical) to 3% (experimental), with 80% power and 5% significance level.\n\nStatistical Analysis:\n\nDescriptive statistics for baseline characteristics and adverse events\n\nKaplan-Meier survival analysis for EFS and OS\n\nSignificance threshold p \\\u003C 0.05\n\nSafety Monitoring:\n\nDaily blood count and coagulation tests during induction\n\nMonitoring and management of adverse events including severe coagulation disorders, differentiation syndrome, arsenic toxicity, infection, and bone marrow suppression\n\nAdverse events graded with CTCAE criteria and reported accordingly\n\nData Handling:\n\nElectronic data capture system compliant with ICH-GCP and CDISC standards\n\nConfidential storage at Xi'an Jiaotong University First Affiliated Hospital\n\nData anonymized for reporting\n\nEthics:\n\nConducted in accordance with the Declaration of Helsinki and Chinese clinical research regulations\n\nProtocol approved by local ethics committee\n\nWritten informed consent required before study enrollment\n\nStudy Timeline:\n\nPlanned start: June 2025\n\nPlanned completion: June 2028",[140],"APL","2026-03-26",{"date":143,"type":38},"2026-03-31",{"date":145,"type":38},"2025-06-01",{"date":147,"type":24},"2028-06",{"name":44,"class":45},1,{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":25,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100622887","phase-3-intravenous-rhpro-uk-before-stroke-thrombectomy-in-the-extended-time-window-bridge-puk-extend-100622887","NCT07389460","Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)","Intravenous rhPro-UK Versus Placebo Before Endovascular Thrombectomy For Stroke Patient With Large Vessel Occlusion In The Extended Time Window: the Randomized, Placebo-controlled, Double-blind Trial (BRIDGE-PUK EXTEND )","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Acute ischemic stroke presenting within 4.5-24 hours of last known well;\n3. No significant pre-stroke functional disability: for age \\\u003C80 years, pre-stroke modified Rankin scale (mRS) ≤2; for age ≥80 years, prestroke mRS ≤1;\n4. Baseline NIHSS score ≥6;\n5. Imaging criteria of BOTH:\n\n1\\. Occlusion on CTA\u002FMRA in one of the following vessels: M1\u002FM2 segment of middle cerebral artery, A1 segment of anterior cerebral artery, V4 segment of vertebral artery, basilar artery, or P1 segment of posterior cerebral artery. For A1, or P1 occlusions, vessel diameter must be ≥0.75 mm; 2. For anterior circulation occlusion: CTP\u002FMRP demonstrating mismatch ratio ≥1.8, absolute mismatch volume ≥15 mL, and ischemic core volume \\\u003C70 mL; OR have a mismatch between the presence of an abnormal signal on MRI diffusion-weighted imaging and no visible signal change on FLAIR. For posterior circulation occlusion: pc-ASPECTS score ≥6.\n\n6\\. Plan to received endovascular thrombectomy; 7. The patient or their legal representative provides written informed consent.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT\u002FMRI;\n2. Onset accompanied by epileptic seizures, resulting in questionable stroke diagnosis and inability to obtain an accurate baseline NIHSS score;\n3. Women who are pregnant or breastfeeding, or have a positive serum β-HCG test upon admission;\n4. Already received intravenous thrombolytic after index stroke;\n5. History of prior intracranial hemorrhage, including cerebral parenchymal hemorrhage, subarachnoid hemorrhage, and subdural\u002Fextradural hematoma;\n6. Active bleeding or bleeding tendency, such as gastrointestinal bleeding, urinary tract bleeding, retinal hemorrhage, etc., or presence of coagulation dysfunction;\n7. History of major recent surgery or trauma, such as intracranial or spinal surgery within the past 3 months, major surgery within the past 2 weeks, or severe head trauma within the past 3 weeks;\n8. Baseline blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL;\n9. Received low molecular weight heparin within 24 hours, or oral anticoagulants with an International Normalized Ratio (INR) \\>1.7, or thrombin inhibitors within 48 hours, among others;\n10. Arterial tortuosity or other vascular anomalies precluding endovascular access to target vessel;\n11. Pre-existing neurological\u002Fpsychiatric disorders interfering with neurological assessment;\n12. Space-occupying intracranial tumors (except for small meningiomas);\n13. Intracranial aneurysm or arteriovenous malformation;\n14. Terminal illness with life expectancy \\\u003C6 months;\n15. Concurrent participation in other investigation clinical trials;\n16. Presence of other conditions deemed by the investigator as unsuitable for participation in the study.",{"count":158,"type":24},820,[137],"This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well. The study will address two primary questions: 1) Whether rhPro-UK enhances pre-thrombectomy reperfusion rates and improves 90-day functional outcomes compared to placebo; 2) Whether rhPro-UK increases the risk of symptomatic intracranial hemorrhage and mortality.\n\nParticipants will be randomized to receive an intravenous bolus of rhPro-UK or matching placebo, with a total dose of 35mg (15mg administered as an intravenous push within 5 minutes, and the remaining 20mg continuously infused intravenously over 30 minutes). Key assessments include repeat neuroimaging (CT\u002FCTA or MRI\u002FMRA) at 24 hours post-treatment to evaluate reperfusion, NIH Stroke Scale score at day 5-7, and modified Rankin Scale score assessment at 90 days. Safety monitoring will focus on hemorrhagic transformation and mortality events throughout the study period.",[162],"Acute Ischemic Stroke",[164,165,166,167,168],"Large Vessel Occlusion Stroke","Recombinant Human Prourokinase","Extended Time Window","Intravenous Thrombolytic Therapy","Endovascular Treatment","2026-02-04",{"date":171,"type":38},"2026-02-05",{"date":173,"type":24},"2026-01-31",{"date":175,"type":24},"2028-03-31",{"name":44,"class":45},10,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":25,"phases":188,"briefSummary":189,"conditions":190,"keywords":194,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":202,"leadSponsor":204,"locationsCount":46},"100606025","effects-of-pfo-closure-on-glymphatic-function-and-clinical-symptoms-in-patients-with-migraine-100606025","NCT07170176","Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine","The Impact of Percutaneous Patent Foramen Ovale Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine","Inclusion Criteria:\n\n1. Adults aged 18 to 60 years.\n2. Diagnosed with patent foramen ovale (PFO) with significant right-to-left shunt.\n3. For the case group: Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders (ICHD-3).\n4. For the control group: No history of migraine.\n5. Willing and able to provide written informed consent.\n6. Education level of primary school or higher.\n\nExclusion Criteria:\n\n1. Patients with a history of PFO closure or other migraine-related surgical treatments;\n2. Patients with other severe cardiac or neurological diseases, mental disorders, or psychological conditions;\n3. Patients with contraindications to closure surgery or MRI scans (e.g., severe infection, coagulation dysfunction, cardiac pacemakers, aneurysm clips, metallic foreign bodies in the eye, non-removable metal dentures, etc.);\n4. Patients unable to complete migraine symptom assessments or imaging examinations due to other reasons.","60 Years",{"count":187,"type":24},150,[27],"Patent Foramen Ovale (PFO) is a common congenital heart defect. Recent studies have suggested a potential association between PFO and migraines, particularly migraine with aura. It is hypothesized that PFO may allow microemboli or vasoactive substances from venous blood to bypass pulmonary metabolism and enter the arterial system directly, potentially triggering migraines. Although PFO closure has been shown to reduce the frequency and severity of migraine attacks, its long-term efficacy and underlying mechanisms require further investigation.\n\nThis study aims to explore the characteristics of glymphatic system function in PFO patients and its relationship with migraine symptoms, as well as the impact of PFO closure on glymphatic function and its role in alleviating migraine symptoms. A case-control and self-controlled before-after study design is adopted. Two groups of participants are enrolled: a case group consisting of PFO patients with significant right-to-left shunt and migraine, and a control group comprising PFO patients with significant shunt but without migraine. According to clinical guidelines and after obtaining informed consent, eligible patients in the case group undergo percutaneous PFO closure.\n\nBy comparing migraine symptoms and glymphatic function indicators both before and after the procedure between the two groups, the interventional effect of PFO closure and its potential mechanism will be investigated. The primary endpoint is the improvement in migraine symptoms, while the secondary endpoints include glymphatic function metrics. The findings of this study will provide new theoretical insights and clinical guidance for the management of PFO-related migraines.",[191,192,193],"Migraine Disorders","Patent Foramen Ovale","Right-to-Left Shunt, Cardiac",[192,195,196,197],"Migraine","Glymphatic System","PFO Closure","2026-01-14",{"date":200,"type":38},"2026-01-16",{"date":198,"type":38},{"date":203,"type":24},"2027-12-31",{"name":44,"class":45},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":25,"phases":214,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":149},"100613428","phase-4-efficacy-and-safety-of-leymovir-versus-valganciclovir-in-prevention-of-cytomegalovirus-infection-and-cytomegalovirus-disease-in-chinese-kidney-transplant-recipients-100613428","NCT07266467","Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients","CAPS01","Inclusion Criteria:\n\n\\- 1) Age ≥18 years old, gender unlimited. 2) Receiving the first kidney transplant. 3) Be within 0 (ie, day of transplantation) to 7 days (inclusive) post-kidney transplant at the time of randomization.\n\n4\\) Obtain informed consent signed .\n\nExclusion Criteria:\n\n* 1)Received a previous solid organ transplant or HSCT. 2)Is a multi-organ transplant recipient (eg, kidney-pancreas). Note: Double kidney transplant recipients (ie, transplant of two kidneys from the same donor to the same recipient simultaneously) will be excluded.\n\n  3)Has a history of CMV disease or suspected CMV disease within 6 months prior to randomization.\n\n  4)Has evidence of CMV viremia at any time from the signing of the ICF or the transplant procedure until the randomization period; 5)Has suspected or known hypersensitivity to active or inactive ingredients of LET formulations, VGCV, GCV, formulations.\n\n  6)Is on dialysis or plasmapheresis at the time of randomization. Note: For the purposes of this protocol, dialysis includes hemofiltration. Participant who: (1) has had dialysis or plasmapheresis within 7 days (inclusive) post-transplant but is not on dialysis or plasmapheresis at the time of randomization; and (2) is expected to remain off dialysis or plasmapheresis may be enrolled, provided that all other inclusion\u002Fexclusion criteria are met.\n\n  7)Has post-transplant renal function of CrCI 10 mL\u002Fmin at randomization (measured) locally). For this exclusion criterion, CrCl will be calculated using the Cockcroft-Gault equation using the most recently obtained and available serum creatinine value collected within 3 calendar days prior to and including the day of randomization and after the conclusion of any clinically warranted (at the discretion of the investigator) post-transplant dialysis or plasmapheresis.\n\n  8)Has Child-Pugh Class C severe hepatic insufficiency at screening. 9)Has both moderate hepatic insufficiency AND moderate-to-severe renal insufficiency at screening.\n\nNote: Moderate hepatic insufficiency is defined as Child-Pugh Class B. moderate-to-severe renal insufficiency is defined as CrCl \\\u003C50 mL\u002Fmin, as calculated by the Cockcroft-Gault equation, respectively.\n\n10)Has any uncontrolled infection on the day of randomization. 11)Has documented positive results for human immunodeficiency virus antibody (HIV-Ab) test at any time prior to randomization, or for hepatitis C virus antibody (HCV-Ab) and with detectable HCV ribonucleic acid (RNA) within 90 days prior to randomization or hepatitis B surface antigen (HBsAg) within 90 days prior to randomization.\n\n12)Requires mechanical ventilation, or is hemodynamically unstable, at the time of randomization.\n\n13)Has a history of malignancy 5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy.\n\n14)Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through at least 90 days following cessation of study therapy.\n\n15)Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or put the participant at undue risk, as judged by the investigator, such that it is not in the best interest of the participant to participate in this study.\n\n16)laboratory value at screening: hemoglobin \\\u003C8g\u002FdL; Or neutrophils \\\u003C1.0\\*109\u002FL; Or platelet \\\u003C25\\*109\u002FL; Serum AST or ALT\\>5×ULN; Or serum total bilirubin \\>2.5×ULN; 17)Has received within 30 days prior to randomization or plans to receive during the study any of the following anti-CMV IgG antibody treatment or anti-CMV drug therapy including: Cidofovirb. CMV hyper-immune globulinc. Any investigational CMV antiviral agent\u002Fbiologic therapy.\n\n18)Has received within 7 days prior to randomization or plans to receive during the study any of the following anti-CMV drug therapy including: LET, GCV, VGCV, Foscarneth, ACV (at doses \\>3200 mg PO per day or \\>25 mg\u002Fkg IV per day), Valacyclovir (at doses \\>3 g PO per day), Famciclovir (at doses \\>1500 mg PO per day).\n\n19)are expected to receive TCM or herbal treatment during study treatment and within 14 days after study administration; 20)Is currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5 x half-life of the investigational compound (excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. Participants previously treated with an investigational monoclonal antibody will be eligible to participate after a 150-day washout period.\n\n21)Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study.\n\n22)Is or has an immediate family member (eg, spouse, parent\u002Flegal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this study.",{"count":213,"type":24},290,[215],"PHASE4","the existing anti-CMV drugs mainly include valganciclovir, ganciclovir and foscarnet sodium, all of which act on DNA polymerase (pUL54), making them prone to cross resistance. DNA synthesis in normal cell is also catalyzed by DNA polymerase, which can also inhibit normal cell production, especially in metabolically active bone marrow cells, leading to bone marrow suppression. In addition, these drugs are mainly metabolized by the kidneys, causing damage to proximal renal tubular cells. Therefore, it is necessary to closely monitor the patient's renal function and adjust the dosage. Overall, the medical demand for effective and well-tolerated treatment methods for CMV infection management in kidney transplant recipients remains unmet, and safer anti-CMV drugs are urgently needed.\n\nThe target of letemovir is the CMV DNA terminal enzyme complex, which is different from the target of existing anti-CMV drugs, and does not exhibit cross resistance. Moreover, this target does not have a corresponding substance in mammalian cells and does not exhibit toxicity similar to DNA polymerase targets. In addition, letemovir is mainly metabolized by the liver, and urinary excretion can be ignored (\\\u003C2% dose), so there is no need to adjust the dose according to renal function. Phase III registered clinical studies abroad have shown that letemovir is not inferior to valganciclovir in preventing CMV disease in kidney transplant recipients. Additionally, letemovir is safer and has a lower incidence of adverse reactions, especially leukopenia or granulocytopenia. However, there is still a lack of data on the use of kidney transplantation in Chinese population.\n\nThe aim of this study was to evaluate the efficacy and safety of letamovir in preventing CMV infection and CMV disease in kidney transplant recipients in China.",[218],"Kidney Transplant",[218,220,221,222,223],"cytomegalovirus","letemovir","valganciclovir","Randomized control","2025-12-04",{"date":226,"type":38},"2025-12-05",{"date":228,"type":38},"2025-05-13",{"date":230,"type":24},"2026-11-30",{"name":44,"class":45},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":25,"phases":241,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":149},"100605881","early-phase-1-novel-bispecific-abtcr-anti-cd19cd22-t-cells-in-relapsed-or-refractory-b-cell-lymphoma-100605881","NCT07168291","Novel Bispecific AbTCR (Anti-CD19\u002FCD22)-T Cells in Relapsed or Refractory B-cell Lymphoma","The Safety and Efficacy of Novel Bispecific AbTCR (Anti-CD19\u002FCD22)-T Cells in Patients With Relapsed or Refractory B-cell Lymphoma: An Open-label, Single-arm Clinical Study","Inclusion Criteria:\n\n1. Age≥ 18 years;\n2. Pathologically diagnosed CD19+\u002FCD22+ B-cell lymphoma;\n3. Relapsed or refractory after at least two prior lines of therapy;\n4. Patient's main organs functioning well:\n\n   1. Cardiac function: Left ventricular ejection fraction ≥50%;\n   2. Liver function: ALT and AST ≤2.5 × upper limit of normal (ULN), total bilirubin ≤2 × ULN;\n   3. Renal function: Serum creatinine ≤3.0 mg\u002FdL (≤260 μmol\u002FL);\n   4. Pulmonary function: ≤CTCAE grade 1 dyspnea and Indoor oxygen saturation ≥92%;\n   5. Adequate bone marrow function as assessed by the investigator to receive lymphodepleting chemotherapy;\n5. Adequate vascular access for leukapheresis;\n6. Women of childbearing potential (all women physiologically capable of becoming pregnant) must agree to use highly effective contraception for 1 year after AbTCR (anti-CD19\u002FCD22)-T cell infusion, such as copper-containing intrauterine device, hormonal implants, or tubal ligation; male subjects with partners of childbearing potential must agree to use effective barrier contraception for 1 year after AbTCR (anti-CD19\u002FCD22)-T cell infusion;\n7. Patient or his or her legal guardian voluntarily participates in and signs an informed consent form.\n\nExclusion Criteria:\n\n1. Lymphoma involving only the central nervous system (CNS), or secondary CNS lymphoma patients judged by the investigator to be at high risk for AbTCR (anti-CD19\u002FCD22)-T cell therapy;\n2. History of other malignancies not in complete remission for at least 2 years (the following conditions are exempt from the 2-year restriction: non-melanoma skin cancer, completely resected stage I tumors with low risk of recurrence, treated localized prostate cancer, biopsy-confirmed cervical carcinoma in situ, or PAP smear showing squamous intraepithelial lesion);\n3. Any of the following at screening:\n\n   1. Positive hepatitis B surface antigen (HBsAg) (regardless of hepatitis B virus DNA copy number);\n   2. Positive hepatitis B core antibody (HBcAb) with increased hepatitis B virus DNA copy number;\n   3. Hepatitis C, human immunodeficiency virus (HIV), or syphilis infection;\n4. Deep vein thrombosis (DVT) or pulmonary embolism (PE) within 3 months prior to signing informed consent;\n5. Ongoing anticoagulant therapy for deep vein thrombosis (DVT) or pulmonary embolism (PE) within 3 months prior to signing informed consent;\n6. Uncontrolled systemic fungal, bacterial, viral, or other infection;\n7. Acute or chronic graft-versus-host disease (GvHD);\n8. History of any of the following cardiovascular diseases within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant heart disease;\n9. History of or current clinically significant CNS disease at screening, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric illness;\n10. Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to starting lymphodepleting chemotherapy;\n11. Use of any of the following drugs or treatments within the specified timeframes prior to leukapheresis:\n\n    1. Alemtuzumab within 6 months prior to leukapheresis;\n    2. Cladribine within 3 months prior to leukapheresis;\n    3. Fludarabine within 3 months prior to leukapheresis;\n    4. Anti-CD20 monoclonal antibody within 7 days prior to leukapheresis;\n    5. Venetoclax within 4 days prior to leukapheresis;\n    6. Idelalisib within 2 days prior to leukapheresis;\n    7. Lenalidomide within 1 day prior to leukapheresis;\n    8. Therapeutic doses of corticosteroids (defined as prednisone or equivalent \\>20 mg\u002Fday) within 7 days prior to leukapheresis; physiological replacement, topical, and inhaled steroids are permitted;\n    9. Non-lymphocytotoxic chemotherapy within 1 week prior to leukapheresis. Oral chemotherapy drugs are allowed if at least 3 half-lives have passed prior to leukapheresis;\n    10. Lymphocytotoxic chemotherapy (e.g., cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan) within 2 weeks prior to leukapheresis;\n    11. Investigational drugs within 4 weeks prior to leukapheresis. However, subjects who had no response or disease progression during experimental treatment and for whom at least 3 half-lives have passed since the last dose prior to leukapheresis are allowed;\n    12. GvHD therapy (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutic agents, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL6, or anti-IL6R) within 4 weeks prior to leukapheresis and AbTCR (anti-CD19\u002FCD22)-T cell infusion;\n    13. Donor lymphocyte infusion (DLI) within 6 weeks prior to AbTCR (anti-CD19\u002FCD22)-T cell administration;\n    14. Radiotherapy within 6 weeks prior to leukapheresis, including large bone marrow areas such as the sternum or pelvis. Patients with progressive disease at irradiated sites or PET-positive lesions at non-irradiated sites are eligible. Radiotherapy to a single site is allowed within 2 weeks prior to leukapheresis if there are PET-positive lesions at other non-irradiated sites;\n    15. If prior immunotherapy such as anti-PD1 or anti-PD-L1 was used, at least 5 half-lives must have passed between the last dose and AbTCR (anti-CD19\u002FCD22)-T cell infusion;\n12. Prior allogeneic hematopoietic stem cell transplantation;\n13. Other conditions considered inappropriate by the researcher.",{"count":240,"type":24},3,[242],"EARLY_PHASE1","This is an open-lable, single arm, non-randomized study to evaluate the primary safety and efficacy of the novel bispecific AbTCR (anti-CD19\u002FCD22)-T cells in patients with relapsed or refractory B-cell lymphoma",[245,246,247],"Diffuse Large B Cell Lymphoma (DLBCL)","Follicular Lymphoma ( FL)","Burkitt Lymphoma",[249,250,251],"AbTCR-T","CD19\u002FCD22","B-cell lymphoma","2025-09-11",{"date":254,"type":38},"2025-09-17",{"date":256,"type":24},"2025-12-31",{"date":98,"type":24},{"name":44,"class":45},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":53,"enrollmentInfo":267,"targetDuration":4,"studyType":25,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":149},"100575707","remote-ischemic-conditioning-for-acute-moderate-ischemic-stroke-due-to-large-artery-atherosclerosis-100575707","NCT06775782","Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis","Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis: A Multi-centered, Open-label, Blind Endpoint, Randomized Controlled Trial","RIC-LAA","Inclusion Criteria\n\n1. Male or female with age from 18 to 85 years old;\n2. Randomization must be within 48 hours after stroke symptom onset;\n3. Ischemic stroke confirmed by MRI diffusion-weighted imaging;\n4. NIHSS score 6-16, or 4-5 with disabling deficits at the time of randomization. The following typically should be considered disabling deficits: Complete hemianopsia (≥2 on NIHSS question 3) or severe aphasia (≥2 on NIHSS question 9), or visual or sensory extinction (≥1 on NIHSS question 11) or any weakness limiting sustained effort against gravity (≥2 on NIHSS question 6 or 7);\n5. Proven large vessel 50%-99% stenosis or occlusion by MRA, CTA or DSA in cervical or intracranial carotid artery, M1 or M2 segments of the middle cerebral artery, A1 segment of anterior cerebral artery, P1 segment of posterior cerebral artery, vertebral artery, or basilar artery. For patients with single cerebral infarction, when MRA indicates \\>50% stenosis rather than occlusion, CTA or DSA should be performed to exclude the risk of MRA overestimating stenosis severity. Acute neurological deficit and cerebral infarction are compatible with ischemia in the vascular territory;\n6. Pre-stroke modified Rankin Scale score (mRS) of 0-1;\n7. Signed Informed Consent obtained.\n\nExclusion Criteria\n\n1. Thrombolysis or endovascular therapy performed or planned for index event;\n2. Suspected or confirmed cardioembolic source of stroke: i. The aetiology of cardiogenic embolism with high embolic potential, such as atrial fibrillation, atrial flutter, rheumatic mitral or aortic stenosis, artificial heart valve, left atrial myxoma, valve neoplasm, left ventricular wall thrombus, congestive heart failure, bacterial endocarditis, cardiomyopathy, myocardial infarction within previous 30 days; ii. Multiple cerebral infarctions in more than one vascular territory (e.g., bilateral MCA, or an MCA and a basilar artery) confirmed MRI diffusion-weighted imaging;\n3. Suspected or confirmed uncommon causes of cerebrovascular disorders: arterial dissection, Moyamoya disease, vasculitis disease, neurosyphilis, radiation induced vasculopathy, fibromuscular dysplasia, benign angiopathy of central nervous system, post-partum angiopathy, suspected vasospastic process, suspected recanalized embolus etc.;\n4. Subclavian artery stenosis ≥ 50% or subclavian steal syndrome;\n5. Refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg after drug treatment);\n6. Evidence of intracranial tumor (except small meningioma), abscess, arteriovenous malformation;\n7. Patients with bleeding propensity: platelet count \\\u003C50×10\\^9\u002FL; heparin was administered within 48 hours with APTT≥35s; on anticoagulant therapy with warfarin and International Normalized Ratio (INR) \\> 1.7;\n8. Undergoing hemodialysis or peritoneal dialysis, or known severe renal insufficiency with glomerular filtration rate \\\u003C30 ml\u002Fmin or serum creatinine \\>220 mmol\u002FL (2.5mg\u002Fdl);\n9. Respiratory failure, including type I and type II;\n10. Any contraindication for Remote Ischemic Conditioning: severe soft tissue injury, fracture, peripheral vascular disease, arteriovenous fistula, or venous thrombosis in the upper limbs;\n11. Severe comorbid condition with life expectancy \\\u003C 6 months；\n12. Current participation in any other investigational trial；\n13. Pregnancy；\n14. Patients not suitable for this clinical study considered by researchers.",{"count":268,"type":24},1150,[27],"Large Artery Atherosclerosis is one of the most prevalent causes of stroke worldwide and is associated with a high risk of disability and recurrent strokes. Remote Ischemic Conditioning (RIC) is a promising therapy, and it has been recommended for further investigation in patients with acute ischemic stroke resulting from large artery atherosclerosis. The primary objective of this study is to assess the efficacy of RIC in patients suffering from acute moderate ischemic stroke due to large artery atherosclerosis.",[162],[273],"Acute Ischemic Stroke；Large Artery Atherosclerosis；Remote Ischemic Conditioning therapy; Randomized Controlled Trial","2025-08-11",{"date":276,"type":38},"2025-08-14",{"date":278,"type":24},"2025-08-10",{"date":280,"type":24},"2027-08-31",{"name":44,"class":45},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":288,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":290,"conditions":291,"keywords":295,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":46},"100599027","real-world-study-evaluating-the-long-term-outcomes-of-pegylated-interferon--2b-treatment-in-the-families-with-clusters-of-hbv-infection-and-unfavorable-prognosis---a-prospective-controlled-multicenter-cohort-study-100599027","NCT07079150","Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study","Inclusion Criteria:\n\n* Meet the criteria for a family cluster of unfavorable prognoses associated with HBV infection: that is, patients with HBV infection in two consecutive generations of blood relatives, and at least one patient with cirrhosis or HCC in two or more generations of blood relatives;\n* Chronic HBV-infected individuals from families with unfavorable prognoses clustering (meeting either (1)+(2) or (1)+(3) criteria): (1) Positive for HBsAg for more than 6 months; (2) Treated with nucleos(t)ide analogs (NAs); (3) Compensated cirrhosis due to hepatitis B (for details, see the \"Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)\");\n* A negative pregnancy test within 24 hours before the first administration of medication in the treatment group (for women of childbearing age);\n* No contraindications for interferon treatment.\n\nExclusion Criteria:\n\n* Patients diagnosed with liver cancer or other systemic tumors before treatment;\n* Patients with contraindications to Peg IFN α-2b use (for details, see the \"Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)\");\n* Peripheral blood counts: WBC \\\u003C 3.0 × 10\\^9\u002FL, PLT \\\u003C 70 × 10\\^9\u002FL;\n* Liver function: ALT \\> 5 × upper limit of normal (ULN), TBIL \\> 2 × ULN; Individuals planning to receive organ transplantation or who have already undergone organ transplantation;\n* Those allergic to interferon or with any contraindication listed in the product information;\n* Any other conditions deemed unsuitable for enrollment by the investigator.",{"count":289,"type":24},1500,"Chronic hepatitis B can develop into cirrhosis and liver cancer, which seriously endangers the life and health of people. In China, HBV is mainly transmitted from mother to child, showing the phenomenon of family clusters. Similarly, cirrhosis and hepatocellular carcinoma occur in familial clusters. Familial clusters of HBV infection with unfavorable prognoses refers to HBV-infected patients from two consecutive generations of blood relatives, with at least one family member diagnosed with hepatitis B-related cirrhosis or hepatocellular carcinoma (HCC). Previous family investigations have shown that the risk and harm of HBV-related cirrhosis and hepatocellular carcinoma are significantly higher in families with familial clusters of HBV infection with unfavorable prognoses than in the general population.\n\nCurrently, antiviral drugs used for CHB mainly include nucleoside analogues (NAs) and interferon-alpha (mainly pegylated interferon-alpha, Peg IFN). NAs mainly inhibits viral replication by blocking the reverse transcription process, but it cannot effectively inhibit the expression of viral proteins such as HBsAg, and rarely achieves clinical cure. Multiple clinical studies have shown that the use of NAs reduces the incidence of cirrhosis decompensation, HCC, and death in patients with CHB compared to untreated or placebo-treated patients. Despite long-term treatment with first-line NAs drugs, CHB patients continue to be at risk of developing hepatocellular carcinoma. Peg IFN α-2b injection is the first-line drug of choice for antiviral treatment of chronic hepatitis B, and its main mechanism of action includes anti-HBV, anti-fibrosis, anti-tumor and regulation of immune response. In 2024, a randomized controlled multicenter study showed that Peg IFN α-2b combined with NAs therapy could effectively prevent hepatocellular carcinoma in CHB patients. There is sufficient evidence in clinical practice that long-term antiviral therapy, whether NAs or Peg IFN α-2b, reduces the risk of cirrhosis, hepatocellular carcinoma, and death in patients with CHB. In conclusion, early antiviral therapy can reduce the risk of developing hepatitis B cirrhosis and hepatocellular carcinoma in CHB patients with familial clusters of HBV infection with unfavorable prognoses.\n\nThe goal of this observational study is to explore the evaluation of pegylated interferon α-2b combined with first-line NAs on the long-term outcome of CHB antiviral therapy with cirrhosis and HCC progression as the main observation targets, compared with only use of NAs in the context of familial clusters of HBV infection with unfavorable prognoses. It is intended to provide high-quality evidence-based medical evidence for the treatment and follow-up of CHB, explore optimal clinical decision-making, and provide global clinical data for the improvement and evaluation of this difficult-to-treat population. The main question it aims to answer is: Can Peg IFN-α-2B combined with NAs therapy improve the long-term outcomes of this particular population of familial clusters of HBV infection with unfavorable prognoses compared to first-line NAs monotherapy? Patients with familial clusters of HBV infection with unfavorable prognoses using Peg IFN-α-2B combined with NAs therapy and NAs monotherapy will be collected laboratory and medical examination data at specified follow-up points, and recorded adverse events and drug combinations in detail for 7 years.",[292,293,294],"Hepatitis B, Chronic (CHB)","Hepatitis B","Hepatitis B Virus (HBV)",[296,297,298,299,300,301],"hepatitis B","family cluster","interferon","antiviral therapy","cirrhosis","hepatocellular carcinoma","2025-07-14",{"date":304,"type":38},"2025-07-22",{"date":306,"type":38},"2025-01-01",{"date":308,"type":24},"2032-01",{"name":44,"class":45},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":317,"minAge":20,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":320,"conditions":321,"keywords":324,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":4},"100589255","the-epidemic-status-and-development-trend-of-hepatitis-c-virus-infection-in-pregnant-women-in-xian-100589255","NCT06952036","The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an","The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an: A 10-Year Retrospective Study","Inclusion Criteria:\n\n1. Pregnant women or parturient women confirmed by blood HCG test.\n2. Patients aged 18 years old and above.\n3. Patients with HCV antibody seropositive or HCV RNA positive from 2014-2023.\n\nExclusion Criteria:\n\n1. Patients without valid telephone numbers.\n2. Duplicate records: For duplicate records of the same pregnant woman, only one record should be kept.","FEMALE",{"count":319,"type":24},200000,"The objectives of this study are to improve HCV linkage-to-care in Chinese women and provide theoretical basis for the scientific formulation of HCV prevention and control strategies for pregnant women.\n\nTo understand the epidemiological changes and status of hepatitis C virus (HCV) infection in pregnant women in Shaanxi province in recent 10 years, and to analyze the main influencing factors of hepatitis C infection in pregnant women.",[322,323],"HCV Infection","HCV Elimination",[325,326,327],"Hepatitis C","HCV elimination","Women of childbearing age","2025-04-23",{"date":330,"type":38},"2025-04-30",{"date":332,"type":24},"2025-04-25",{"date":256,"type":24},{"name":44,"class":45},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":19,"minAge":185,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":25,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":359,"locationsCount":149},"100586008","hypotension-prediction-index-and-intraoperative-hypotension-incidence-100586008","NCT06909786","Hypotension Prediction Index and Intraoperative Hypotension Incidence","Effect of Intraoperative Implementation of the Hypotension Prediction Index (HPI) Guided Management Strategy on Incidents of Intraoperative Hypotension Among Frail Patients Undergoing Major Abdominal Surgery","Inclusion Criteria:\n\n* Age\\> 60 years old\n* Frail score \\> 2\n* ASA≥2\n* Planned to receive general anesthesia\n* Elective laparoscopic or laparotomy major abdominal surgery with an expected duration of \\> 180 minutes\n* Planned to receive an arterial line monitoring intraoperatively\n* Being able to give written informed consent prior to surgery\n\nExclusion Criteria:\n\n* Severe cardiac arrhythmia including atrial fibrillation\n* Severe aortic stenosis\n* Uncontrolled Hypertension (sitting systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥100 mmHg during screening)\n* Significant hypotension before surgery defined as a MAP \\\u003C65mmHg\n* Chronic kidney disease with glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m2 or requiring renal-replacement therapy for end-stage renal disease\n* Organ transplant surgery, surgery involving the kidney, liver surgery requiring hilar blockage, surgery requiring controlled hypotension or controlled low central venous pressure",{"count":343,"type":24},100,[27],"This study aim to implement intraoperative hemodynamic monitoring and management guided with HPI algorithm in frail patients undergoing elective abdominal surgery. Investigators hypothesize that the use of this algorithm will alter treatment of hypotension and reduces the amount of hypotension as measured by the time weighted average (TWA) during non-cardiac surgery and to anticipate a reduction of postoperative AKI incidents, to explore the clinical benefits of impact of Acumen guided algorithm hemodynamic management in postoperative intestinal function recovery, and postoperative cardiac complications.",[347],"Intraoperative Hypotension",[349,350,351,352],"intraoperative hypotension","hypotension prediction index","frail patient","acute kidney injury","2025-03-27",{"date":355,"type":38},"2025-04-04",{"date":357,"type":24},"2025-04-01",{"date":256,"type":24},{"name":44,"class":45},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":25,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100582289","bivalirudin-with-prolonged-infusion-during-pci-versus-heparin-after-fibrinolytic-therapy-100582289","NCT06861374","Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic Therapy","Bivalirudin Plus High-Dose Infusion Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Fibrinolysis: a Randomized Trial","BRIGHT-FIT","Inclusion Criteria:\n\n* Any age\n* STEMI patients received fibrinolysis therapy within 12h of symptom onset and are planned to undergo PCI within 24h of symptom onset.\n* Dual antiplatelet drugs must be administrated according to guidelines before PCI (loading doses and maintenance doses of aspirin and clopidogrel or ticagrelor)\n* Patients requiring staged revascularization of non-culprit vessels within 30 days may be enrolled. In such cases the same antithrombotic agents and PCI procedures must be used in the staged procedure consistent with the index procedure PCI, in particular the assigned antithrombin agent heparin vs. bivalirudin);\n* The subject or legal representative has been informed of the nature of the study, understood the provisions of the protocol, was able to ensure adherence, and signed informed consent.\n\nExclusion Criteria:\n\n* Not suitable for PCI;\n* Mechanical complications (such as ventricular septal rupture, papillary muscle rupture with acute mitral regurgitation, etc.);\n* Cardiogenic shock(Killip IV)\n* Known allergy or contraindications to heparin, bivalirudin, aspirin, or both clopidogrel and ticagrelor\n* Patients who underwent PCI in past 30 days\n* Patients in whom the investigators consider inappropriate to participate in this study (eg, have participated in another drug\u002Finstrument study or undergoing another drug\u002Finstrument study, pregnancy).",{"count":369,"type":24},2400,[27],"This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis. Participants will be randomly assigned in a 1:1 ratio to receive either bivalirudin or heparin, with follow-up at 30 days and 1 year. The primary endpoint is a composite of all-cause mortality and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 30 days.",[82],[374],"STEMI, PCI, fibrinolysis, bivalirudin, heparin, bleeding, mortality","2025-03-03",{"date":377,"type":38},"2025-03-06",{"date":379,"type":24},"2025-05",{"date":381,"type":24},"2029-03",{"name":44,"class":45},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100581786","the-value-of-combined-detection-of-different-blood-biomarkers-in-the-diagnosis-and-treatments-of-traumatic-brain-injury-100581786","NCT06854835","The Value of Combined Detection of Different Blood Biomarkers in the Diagnosis and Treatments of Traumatic Brain Injury","Inclusion Criteria:\n\n1. Age: 18-65 years old\n2. Time of injury: patients with acute traumatic brain injury within 24h\n3. Glasgow Coma Scale (Glasgow Coma Scale, GCS) score: 13 to 15 for patients with mild traumatic brain injury, 9 to 12 for moderate traumatic brain injury, and 3 to 8 for patients with severe traumatic brain injury\n4. No other system damage has occurred\n5. Admitted to hospital for the first diagnosis after the injury\n\nExclusion Criteria:\n\n1. With a history of neurological or psychiatric disorders\n2. Traumatic brain injury occurred before the injury\n3. History of alcohol or substance abuse\n4. Mild brain trauma is a complication of other injuries (systemic trauma, facial trauma, or spinal cord trauma) or other causes (psychological trauma, language impairment)\n5. Patients without visits, and incomplete data during treatment","65 Years",{"count":391,"type":24},80,"TBI, as a potential risk factor, causes a 1.5 times higher risk of neurodegenerative disease to up to 30-70% of TBI patients with neurological symptoms. Brain trauma is an important global medical, public health and social problem. Early diagnosis and effective treatment can effectively reduce the disability rate of patients and the incidence of neurological sequelae, and has increasingly become the focus of the international scientific research community. Exploring blood-based biomarkers has potential clinical value, which can greatly help clinicians to evaluate patients' conditions and develop reasonable plans, and then improve the clinical management and treatment of patients with craniocerebral trauma. Further research work is needed to be done to identify the most effective and efficient biomarker or combination marker strategies for integration into clinical treatment.",[394,395],"Brain Injuries, Traumatic","Biomarkers","2025-02-25",{"date":375,"type":38},{"date":399,"type":24},"2025-03-15",{"date":401,"type":24},"2027-07-31",{"name":44,"class":45},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":19,"minAge":411,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":25,"phases":415,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":46},"100574742","abdominal-transcutaneous-electrical-acupoint-stimulation-on-children-with-autism-spectrum-disorder-100574742","NCT06763237","Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder","Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder: A Randomized Clinical Trial","TEAS\u002FASD","Inclusion Criteria:\n\n* Being diagnosed as autism based on the DSM-V and Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)\n* Aged 3 to 6 years\n\nExclusion Criteria:\n\n* Diagnosed with other organic diseases (such as severe hearing and visual impairment, brain trauma) and neurological disease (e.g., epilepsy, Rett syndrome), or psychiatric disorder (schizophrenia, bipolar affective disorder, etc)\n* Oral or injected antibiotics within 30 days before screening\n* History of acupuncture, electroacupuncture, TEAS treatment before screening\n* Taking antipsychotic drugs and psychobiotic supplements within 30 days before screening","3 Years","6 Years",{"count":414,"type":24},42,[27],"The goal of this clinical trial is to learn if abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS) works to treat autism spectrum disorder (ASD) in children. It will also learn about the safety of abdominal TEAS. The main questions it aims to answer are:\n\nDoes abdominal TEAS a safe and effective treatment for children with autism spectrum disorder and gastrointestinal symptoms? Researchers will compare abdominal TEAS to a placebo (a sham abdominal TEAS without stimulation) to see if abdominal TEAS works to treat ASD.\n\nParticipants will:\n\nTake abdominal TEAS or sham abdominal TEAS 5 days a week for 8 weeks. Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms.",[418,419],"Autism Spectrum Disorder","Autism in Children",[421,422,423,424],"Transcutaneous electrical acupoint stimulation","Gastrointestinal symptoms","Children","Autism spectrum disorder","2025-01-02",{"date":427,"type":38},"2025-01-08",{"date":429,"type":24},"2025-01-10",{"date":431,"type":24},"2026-01-10",{"name":44,"class":45},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":19,"minAge":440,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":25,"phases":444,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":149},"100525754","early-phase-1-nggt006-gene-therapy-for-homozygous-familial-hypercholesterolemia-100525754","NCT06125847","NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia","A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Homozygous Familial Hypercholesterolemia With LDLR Mutations","Inclusion Criteria:\n\n* Voluntarily sign informed consent form;\n* Male or female, 12 ≤ age ≤ 55 years (first patient≥ 18 years), diagnosed as homozygous familial hypercholesterolemia with genetic confirmation of two mutant alleles of the LDL receptor (LDLR) gene;\n* AAV8 neutralizing antibodies can be negative or reduced to negative levels through methods such as plasma exchange.\n* Untreated LDL-C ≥10 mmol\u002FL (386mg\u002F dL) or treated LDL-C ≥7 mmol\u002FL (270mg\u002F dL) together with cutaneous or tendon xanthoma before age 18 years;\n* Had been on stable medication for ≥30 days if receiving lipid-lowering therapy (or ≥60 days if receiving alirocumab or evolocumab) prior to screening and not scheduled for addition of new drugs or dose adjustments during the study;\n* Agreed to follow a low-fat diet and comply with all study procedures;\n* Agreed to maintain a similar exercise volume and intensity to baseline during the study period;\n* Agreed to maintain good lifestyle habits;\n* No history of alcohol abuse or alcohol dependence (diagnosed as F10 in ICD-10 code);\n* No sexual activity for 14 days prior to administration and negative serum pregnancy test in female participants;\n* Participants of childbearing potential agreed to use highly effective contraception for at least 365 days from administration of NGGT006;\n* No plan of stent implantation within 3 months.\n\nExclusion Criteria:\n\n* Positive for hepatitis B surface antigen, hepatitis C, human immunodeficiency virus (HIV) or syphilis test;\n* Clinically significant abnormalities in liver function test: alanine aminotransferase (ALT) ≥2 × upper limit of normal (ULN) and\u002For aspartate aminotransferase (AST) ≥2 × ULN;\n* Baseline blood pressure ≥160\u002F100 mmHg (1 repeat measurement is allowed);\n* Uncontrolled myocardial infarction or heart failure, or had surgery plan within 1 year;\n* Diabetes diagnosed within 3 months or with poor control (HbA1c ≥9%);\n* Acute or chronic kidney failure;\n* Hemoglobin (Hb) ≥120g\u002FL (male), Hb ≥110 (female);\n* Abnormal platelet counts or morphology;\n* History or laboratory tests suggestive of thrombosis;\n* Had contraindications to glucocorticoid (e.g., epilepsy, severe schizophrenia, active peptic ulcer);\n* Life expectancy less than 1 year;\n* With malignant tumors;\n* Liver fibrosis or liver cancer;\n* Previous gene therapy treatment;\n* Hypersensitivity to AAV or cortisone or immunosuppressants (sirolimus, rituximab, tacrolimus);\n* Participation in any other clinical trial within 3 months;\n* History of stent implantation within 1 month or myocardial infarction within 3 months;\n* Breastfeeding females;\n* Any other condition that may not be appropriate for the study in the opinion of the Investigator.","12 Years","55 Years",{"count":443,"type":24},12,[242],"This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR mutations. NGGT006 is an adeno-associated viral (AAV) vector carrying codon-optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoting the clearance of low-density lipoprotein cholesterol (LDL-C).",[447],"Homozygous Familial Hypercholesterolemia",[449,450,451],"Homozygous familial hypercholesterolemia","Gene therapy","Low-density lipoprotein cholesterol","2024-12-04",{"date":454,"type":38},"2024-12-09",{"date":456,"type":38},"2023-10-29",{"date":458,"type":24},"2028-11",{"name":44,"class":45},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":467,"enrollmentInfo":468,"targetDuration":4,"studyType":25,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":4},"100570181","conventional-partial-pancreatoduodenectomy-versus-an-extended-pancreatoduodenectomy-for-pancreatic-head-cancers-100570181","NCT06703905","Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers","Short and Long-term Outcomes of Minimally Invasive Pancreatoduodenectomy Combined with Triangle Operation for Resectable Pancreatic Cancer: an International Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Preoperative: a. Patients with suspected or histologically verified resectable, borderline or locally advanced pancreatic cancer of the pancreatic head (i.e. pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN)-carcinoma or periampullary cancer of the pancreatobiliary-type) ; b. Patients scheduled for elective partial pancreatoduodenectomy (irrespective of neoadjuvant therapy); c. Assumed resectability in accordance with the surgical protocol for experimental and control intervention as judged by the treating surgeon; d. Ability of the subject to understand character and individual consequences of the clinical trial;e.Written informed consent; f. Age ≥ 18 years;\n2. Intraoperative: a.No distant metastases; b.No paraaortic lymph node metastases; c.Intraoperative confirmation that the patient can be operated on according to both surgical methods.\n\nExclusion Criteria:\n\n1. Participation in another interventional trial with the interference of intervention and outcome of this trial;\n2. American Society of Anesthesiologists (ASA) grade \\>3;\n3. Distant metastatic disease .","100 Years",{"count":469,"type":24},270,[27],"The goal of this clinical trial is to learn if traditional pancreaticoduodenectomy (PD) combined with TRIANGLE (extended PD surgery) can increase disease-free survival (DFS) in patients with pancreatic head cancers compared to traditional minimally invasive PD. The main questions it aims to answer are:\n\n* Does extended PD surgery increase disease-free survival (DFS)?\n* Does extended PD surgery could improve postoperative and long-term quality of life for patients? Researchers will compare extended PD surgery to traditional PD surgery to see if extended PD surgery could extend the survival time of patients.\n\nParticipants will:\n\n* Accept traditional minimally invasive PD surgery or minimally invasive PD combined with TRIANGLE surgery.\n* Visit the clinic once every 3 months for checkups and tests.\n* Keep a diary of their symptoms.",[473],"Pancreatic Cancer Resectable",[475,476,477,478],"Pancreatic cancer","pancreaticoduodenectomy","Minimally invasive surgery","Heidelberg Triangle","2024-11-21",{"date":40,"type":38},{"date":482,"type":24},"2024-12",{"date":484,"type":24},"2028-12",{"name":44,"class":45},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":18,"sex":19,"minAge":493,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":512,"locationsCount":149},"100560295","predicting-cerebral-palsy-in-infants-with-white-matter-injury-using-mri-100560295","NCT06575283","Predicting Cerebral Palsy in Infants With White Matter Injury Using MRI","Early Prediction of Cerebral Palsy by MRI in Infants With White Matter Injury: a Multicenter Study","Inclusion Criteria:\n\n1. Infants and children at high risk of periventricular white matter injury (PVWMI) (gestational age \\\u003C35 weeks, birth weight \\\u003C2.6 kg, forceps-assisted delivery\u002Ffetal head attraction, Apgar score \\\u003C7, hypoglycaemia, sepsis, electrolyte disturbances, premature rupture of membranes);\n2. Those who underwent MRI at 6 months of age-2 years, including at least T1WI and T2WI sequences;\n3. Upon follow-up, the patient's clinical diagnosis: cerebral palsy, other diagnoses that did not develop into cerebral palsy, or inability to confirm the diagnosis).\n\nExclusion Criteria:\n\n1. Incomplete MRI images or unreadable images due to motion artefacts;\n2. Incomplete neurobehavioural assessment data (including: gross motor function).","6 Months","2 Years",{"count":496,"type":24},1000,"The goal of this study is to determin the MRI features associated with cerebral palsy and to develop prediction models of pediatric disorders by combining MRI with artificial intelligence.\n\nThe main questions it aims to answer are:\n\n* How to achieve features on conventional MRI associated with cerebral palsy?\n* How to predict the risk of cerebral palsy in infants aged 6 to 2 years based on conventional MRI and deep learning? Researchers will compare characteristics of periventricular white matter injury with cerebral palsy to those without cerebral palsy.\n\nParticipants will be asked to provide MRI data, clinical diagnoses information, and follow-up outcomes.",[499,500],"Cerebral Palsy","Periventricular White Matter Abnormalities",[502,503,504,505],"Cerebral palsy","Periventricular white matter injury","MRI","Deep learning","2024-09-04",{"date":508,"type":38},"2024-09-19",{"date":510,"type":24},"2024-09-01",{"date":256,"type":24},{"name":44,"class":45},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":25,"phases":523,"briefSummary":524,"conditions":525,"keywords":528,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":539,"locationsCount":149},"100559730","intravascular-ultrasound-guided-pci-in-patients-with-chronic-kidney-disease-100559730","NCT06567938","Intravascular Ultrasound-Guided PCI in Patients With Chronic Kidney Disease","Intravascular Ultrasound-Guided or Angiography-Guided Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease: The IVUS-CKD Trial","IVUS-CKD","Inclusion Criteria:\n\n* CKD patients with eGFR\\\u003C60 mL\u002Fmin\u002F1.73 m\\^2\n* De novo coronary lesion suitable for second-generation metallic drug-eluting stent placement and IVUS imaging\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Onset of STEMI within 24 hours or emergent angiography\n* Pregnant or childbearing women\n* Co-morbidity with an estimated life expectancy of \\\u003C 1 year\n* LVEF ≤ 30%\n* Cardiogenic shock or hemodynamic instability\n* Severe hepatic dysfunction, defined as ALT or AST more than 5 times the ULN\n* PCI within the previous 12 months\n* Target lesion of stent thrombosis or in-stent restenosis\n* Any planned non-cardiac surgery within 12 months\n* Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk\n* Current enrolment in other clinical trials\n* Contraindication to anti-platelet agents\n* History of intracranial or gastrointestinal bleeding requiring transfusion or surgical intervention for control (excluding hemorrhoid)\n* Chronic total occlusion lesion with unsuccessful guidewire crossing\n* Current intake of nephrotoxic medications (e.g., nonsteroidal anti-inflammatory drugs except acetylsalicylic acid, phenylbutazone, aminoglycosides, amphotericin B, polymyxin, platinum complexes)\n* Immune-related kidney disease or on hormone therapy (e.g. lupus nephritis, IgA nephropathy)\n* Planned exposure to contrast within 72 h after the procedure, intravascular administration of contrast within the previous 5 days\n* Intake of anticoagulants\n* Hemoglobin \\\u003C60 g\u002FL\n* Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial\n* Patients allergic to metals or contrast",{"count":522,"type":24},1528,[27],"The IVUS-CKD study is a prospective, randomized controlled, multicenter trial to determine whether the intravascular ultrasound (IVUS)-guided percutaneous coronary intervention is superior to the angiography-guidance in chronic kidney disease (CKD) patients with respect to target vessel failure (TVF) at 12 months after randomization.",[526,527],"Coronary Artery Disease","Chronic Kidney Diseases",[526,529,530,531,532],"Chronic Kidney Disease","Percutaneous Coronary Intervention","Intravascular Ultrasound","Randomized Trial","2024-08-21",{"date":535,"type":38},"2024-08-23",{"date":537,"type":38},"2024-07-25",{"date":67,"type":24},{"name":44,"class":45},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":149},"100554820","risk-stratification-and-early-prevention-strategies-for-non-compaction-of-ventricular-myocardium-captain-100554820","NCT06504056","Risk Stratification and Early Prevention Strategies for Non-compaction of Ventricular Myocardium (CAPTAIN)","Risk Stratification and Early Prevention Strategies for Non-compaction of Ventricular Myocardium (CAPTAIN): a Multicenter, Retrospective-prospective, Cohort Study","Inclusion Criteria:\n\n* The diagnosis of nvm was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.\n* Patients or their families agreed to participate in the study and authorized informed consent.\n\nExclusion Criteria:\n\n* Incomplete clinical data.\n* Do not agree to the inclusion or refuse to authorize the informed consent.",{"count":548,"type":24},2000,"This study intends to retrospectively-prospectively enroll NVM patients from multiple centers to establish a natural population cohort of NVM patients. By collecting clinical data and biological samples from surgical patients, the investigators will construct a prognosis prediction system for NVM, optimize risk stratification, explore new strategies for the early prevention and treatment of NVM, and improve the efficiency of clinical treatment of NVM patients.",[551],"Isolated Noncompaction of the Ventricular Myocardium",[551,553],"Prognostic factors","2024-07-19",{"date":556,"type":38},"2024-07-22",{"date":558,"type":24},"2024-10-30",{"date":560,"type":24},"2030-09-01",{"name":44,"class":45},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":25,"phases":571,"briefSummary":572,"conditions":573,"keywords":575,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":149},"100554478","phase-4-clinical-study-of-irinotecan-liposome-combination-therapy-for-advanced-gastric-cancer-100554478","NCT06499610","Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer","Prospective, Open-label, Single-arm Clinical Study of Irinotecan Liposomes Combined With Cindilizumab and Lunvalatinib as Second-line Treatment for Adenocarcinoma of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* The patient was fully aware of the study and volunteered to participate in and signed the informed consent form (ICF);\n* Age≥18 years old;\n* Expected survival time of 3 months;\n* Patients with pathologically confirmed advanced gastric cancer and adenocarcinoma of the gastroesophageal junction;\n* Failure or intolerance of previous first-line anti-tumor therapy;\n* CPS 1 was detected by PD-L1 expression level;\n* According to RECIST1.1 criteria, the patient has at least one measurable diameter target lesion (long diameter of tumor lesion CT scan 10mm, short diameter of lymph node lesion CT scan 15mm and scanning layer thickness of 5mm);\n* Bone marrow function: neutrophils 1.5109 \u002F L, platelets 100109 \u002F L, and hemoglobin 75g \u002F L;\n* The ECOG score is 0-2 points;\n* Liver and kidney function: upper limit of 1.5 times normal value of serum creatinine; upper limit of normal value of AST and ALT (upper limit of normal value of 5 times for patients with liver invasion); upper limit of normal value of total bilirubin (upper limit of normal value of 3 times for patients with liver invasion);\n* Women of childbearing age must have a negative pregnancy test (serum) within 7 days before enrollment, and must be willing to use appropriate methods for contraception during the trial;\n* Consent to provide the histological samples;\n\nExclusion Criteria:\n\n* Allergic reaction to any study drug or its ingredients;\n* Patients with severe hepatic and renal insufficiency;\n* Have used a strong CYP3A4 inducer within 2 weeks before the first dose of the trial drug, or have used a strong CYP3A4 inhibitor or a strong UGT1A1 inhibitor within 1 week;\n* Uncontrollable systemic diseases (such as advanced infection, uncontrolled hypertension, diabetes mellitus, etc.);\n* Patients with intestinal obstruction and gastrointestinal bleeding;\n* According to the HER 2 testing process and evaluation criteria in CSCO Guidelines for Diagnosis and Treatment of Gastric Cancer 2024 edition: confirmed by immunohistochemistry (IHC), HER2 2 + accompanied by in situ hybridization with gene amplification or HER2 3 +;\n* Have any active autoimmune disease or a history of autoimmune disease, such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, and reduced thyroid function (which can be included after normal hormone replacement therapy);\n* Heart function and disease are one of the following:\n\n  1. Long QTc syndrome or QTc interval\\> 480 ms;\n  2. Complete left bundle branch block, degree II or III atrioventricular block;\n  3. Severe, uncontrolled arrhythmias requiring medical therapy;\n  4. New York Society of Cardiology grade III;\n  5. Cardiac ejection fraction (LVEF) below 50%;\n  6. history of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, clinically severe pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to recruitment.\n* Uncontrolled ascites and abdominal cavity infection;\n* Active infection of hepatitis B and C (positive for HBV surface antigen and 1x103 copies \u002F mL and 1x103 copies \u002F mL);\n* Human immunodeficiency virus (HIV) infection (HIV antibody positive);\n* Previous or current other malignancies (except basal cell carcinoma of the skin with non-melanoma, carcinoma of the breast \u002F cervix in situ, and other malignancies that have been effectively controlled without treatment in the past five years);\n* Pregnant and lactating women and patients of childbearing age who are unwilling to take contraception;\n* Other investigator judged ineligible for this study.",{"count":570,"type":24},44,[215],"This study is a single-arm, single-center, exploratory clinical study. It is expected that 44 patients with advanced gastric and gastroesophageal junction adenocarcinoma with first-line treatment failure will be included to receive irinotecan liposomes combined with cindilizumab and renvalatinib. The study unit is the First Affiliated Hospital of Xi'an Jiaotong University. The study included screening period (28 days), treatment period (6 cycles), and follow-up period. Subjects signed the informed consent and underwent baseline examination during the screening period, patients meeting the exclusion criteria entered the treatment period, and all subjects completed the protocol to observe safety, tolerability and efficacy. The same subject received only one dosing schedule during the study period. The follow-up period begins after the end of the treatment period.",[574],"Gastric Cancer",[576,577,578],"Irinotecan lipoposomes","And adenocarcinoma of advanced gastric cancer and gastroesophageal junction","Second line treatment","2024-07-11",{"date":581,"type":38},"2024-07-12",{"date":583,"type":24},"2024-07-15",{"date":585,"type":24},"2027-10-15",{"name":44,"class":45},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":133,"enrollmentInfo":594,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":149},"100543165","risk-stratification-and-new-early-prevention-and-treatment-strategies-for-patients-with-cardiomyopathy-strength-100543165","NCT06352320","Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH）","Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH Trial): a National Multi-center, Retrospective-prospective, Cohort Study","Inclusion Criteria:\n\n* Age \\>18 years old.\n* The diagnosis of cardiomyopathy was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.\n* Patients or their families agreed to participate in the study and authorized informed consent.\n\nExclusion Criteria:\n\n* Incomplete clinical data.\n* Do not agree to the inclusion or refuse to authorize the informed consent.",{"count":595,"type":24},500,"This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.",[598],"Cardiomyopathies",[598,553],"2024-07-10",{"date":581,"type":38},{"date":603,"type":38},"2024-05-09",{"date":605,"type":24},"2032-08-31",{"name":44,"class":45},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":616,"conditions":617,"keywords":619,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":621,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":625,"locationsCount":149},"100543164","risk-stratification-early-prevention-and-treatment-strategies-for-arrhythmogenic-cardiomyopathy-100543164","NCT06352307","Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy","Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy (STARTER): a Multicenter Retro-prospective Cohort Study","STARTER","Inclusion Criteria:\n\n* Age \\>18 years old.\n* The diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.\n* Patients or their families agreed to participate in the study and authorized informed consent.\n\nExclusion Criteria:\n\n* Incomplete clinical data.\n* Do not agree to the inclusion or refuse to authorize the informed consent.",{"count":289,"type":24},"This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.",[618],"Arrhythmogenic Cardiomyopathy",[620,553],"Arrhythmogenic cardiomyopathy",{"date":581,"type":38},{"date":623,"type":38},"2024-04-09",{"date":605,"type":24},{"name":44,"class":45},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":634,"targetDuration":4,"studyType":25,"phases":636,"briefSummary":637,"conditions":638,"keywords":642,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":646,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":149},"100531407","safety-and-efficacy-of-xj-procedure-in-patients-with-acute-type-a-aortic-dissection-surgery-100531407","NCT06199401","Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery","Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery (ADVANCED-XJ-Ⅱ): A National, Multi-center, Open-label, Randomized, Controlled, Blinded-end Point Trial","ADVANCED-XJ-Ⅱ","Inclusion Criteria:\n\n* Age 18-70 years;\n* Patients with ATAAD attending the relevant department who have been assessed by a clinician as needing \"Sun's procedure\".\n\nExclusion Criteria:\n\n* Severe aortic root involvement (root diameter \\>45 mm, root tear, severe destruction of the aortic root, combined valve disease);\n* Combined coronary artery disease requiring concomitant coronary revascularization;\n* Prior aortic or cardiac surgery;\n* Preoperative severe malperfusion syndromes such as: severe cerebral complications (acute cerebral infarction, cerebral hemorrhage, coma, etc.); malperfusion of abdominal organs or lower extremities \\>12 h;\n* Preoperative combination of severe single or multiple organ failure;\n* Pregnant women;\n* Refused to sign the informed consent form and refused to participate in this study.",{"count":635,"type":24},680,[27],"This is a national, multicenter, open-label, randomized, controlled, endpoint-blinded clinical trial of patients diagnosed with ATAAD and undergoing \"Sun's procedure\" coordinated by the First Affiliated Hospital of Xi'an Jiaotong University, China. Per the protocol, \"Sun's procedure\" combined with \"XJ-Procedure\" in the anastomosis of the aortic root and Sun's procedure combined with regular suturing methods of the aortic root will be compared.",[639,640,641],"Type A Aortic Dissection","Complication of Surgical Procedure","Aortic Diseases",[639,643,644,645],"Aortic Root Reinforcement","Cardiovascular Surgery","Postoperative Complication",{"date":581,"type":38},{"date":648,"type":38},"2024-01-11",{"date":650,"type":24},"2027-12-01",{"name":44,"class":45},""]